Correction to: Defining hyperphagia for improved diagnosis and management of MC4R pathway–associated disease: a roundtable summary
File(s)
Correction
Author(s)
Type
Journal Article
Abstract
All roundtable participants received honorarium and travel reimbursements from Rhythm Pharmaceuticals, Inc. Authors were not paid for their participation in this manuscript. SBH is a medical advisory board member for Tanita Corporation, Amgen, Novo Nordisk, Versanis Bio, and Medifast and has served as an Amazon Scholar KC is a primary investigator for Rhythm Pharmaceuticals, Inc. and her research group has received research support from Rhythm Pharmaceuticals, Inc. BD is a consultant for Novo Nordisk and primary investigator for Rhythm Pharmaceuticals, Inc. APG has been a consultant for Evidera, Helsinn Healthcare, Idera Pharmaceuticals, Rhythm Pharmaceuticals, Inc., Soleno Therapeutics, Tonix Pharmaceuticals, and Veda Ventures; has been an advisory board member for Millendo Therapeutics and Radius Health; has been a member of the Data Safety Monitoring Committee for Novo Nordisk; has received speaker honoraria from Novo Nordisk and Rhythm Pharmaceuticals, Inc.; and has been a Principal Investigator for clinical trials sponsored by Millendo Therapeutics, Rhythm Pharmaceuticals, Inc., and Soleno Therapeutics. AMH has received grants from the Weston Family Microbiome Initiative and Canadian Institutes of Health Research and is an advisory board member for Rhythm Pharmaceuticals, Inc., the 2023 Novo Nordisk Pediatric Expert Obesity National, and Foundation for Prader-Willi Research USA. She is PI for clinical trials with Rhythm Pharmaceuticals, Inc., Acadia Pharmaceuticals, NovoNordisk, and Eli Lilly. PK has participated on a safety board for and their institution has received funding for clinical trial research from Rhythm Pharmaceuticals, Inc. JR is on speaker bureaus for Eli Lilly, Novo Nordisk, and Rhythm Pharmaceuticals, Inc. and is an independent consultant for Palatin Technologies. CLR’s institution has received research support from Rhythm Pharmaceuticals, Inc. EvdA’s institution has received funding for clinical trial research from Rhythm Pharmaceuticals, Inc. MW has received consulting fees and payment for educational events/lectures from Rhythm Pharmaceuticals, Inc. and their institution has received funding for clinical trial research from Rhythm Pharmaceuticals, Inc. JAY reports grant support from Soleno Therapeutics and Rhythm Pharmaceuticals, Inc. for obesity-related projects as well as material support for research from Hikma Pharmaceuticals plc and Versanis Bio. Regarding the article, Defining Hyperphagia for Improved Diagnosis and Management of MC4R Pathway–Associated Disease: A Roundtable Summary, the authors were informed after publication that two mentions of the gene SNORD116 would be more accurate if updated to SNORD115 (1). While the current reference does support SNORD116 having a role in food intake/body weight, the serotonin receptor regulation is reported specifically with SNORD115. (1) Qi Y, Purtell L, Fu M, Lee NJ, Aepler J, Zhang L, et al. Snord116 is critical in the regulation of food intake and body weight. Sci Rep. 2016;6:18614. https://doi.org/10.1038/srep18614
Date Issued
2025-12-01
Date Acceptance
2025-02-21
Citation
Current Obesity Reports, 2025, 14 (1)
ISSN
2162-4968
Publisher
Springer
Journal / Book Title
Current Obesity Reports
Volume
14
Issue
1
Copyright Statement
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2025. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
License URL
Identifier
https://www.ncbi.nlm.nih.gov/pubmed/40067578
PII: 10.1007/s13679-025-00616-0
Publication Status
Published
Coverage Spatial
United States
Article Number
23
Date Publish Online
2025-03-11